Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -2.59%10 3-1 Month Momentum % is -24.62% as of Jul. 31, 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,389 Biotechnology companies, Upstream Bio ranks worse than 75.59% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-31), Upstream Bio's 3-1 Month Momentum % is -24.62%.
The industry rank for Upstream Bio's 3-1 Month Momentum % or its related term are showing as below:
UPB's 3-1 Month Momentum % is ranked worse than 75.59% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs UPB: -24.62
Upstream Bio (NAS:UPB) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Upstream Bio 3-1 Month Momentum % Related Terms
UPB vs RCKT, ABEO, INDP: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Upstream Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Upstream Bio's 3-1 Month Momentum % falls into.
Upstream Bio (NAS:UPB) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a 3-1 Month Momentum % of -24.62% as of Jul. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Upstream Bio and its competitors. According to the industry distribution chart, Upstream Bio ranks #1050 out of 1389 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Upstream Bio's 3-1 Month Momentum % too high?
Upstream Bio's current 3-1 Month Momentum % is -24.62%. Based on the distribution chart, Upstream Bio ranks #1050 out of 1389 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's 3-1 Month Momentum % compare to RCKT and ABEO?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #1050 out of 1389 companies for 3-1 Month Momentum %. This places Upstream Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Upstream Bio and its competitors. Upstream Bio's current 3-1 Month Momentum % is -24.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current 3-1 Month Momentum % of -24.62%. The current 3-1 Month Momentum % is -24.62%. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Upstream Bio (UPB), the current 3-1 Month Momentum % is -24.62% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
